Madrigal Pharmaceuticals Inc Total Liabilities
Madrigal Pharmaceuticals Inc total liabilities. Based on the latest financial reports, Madrigal Pharmaceuticals Inc (MDGL) has total liabilities worth $656.90 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See how many days can Madrigal Pharmaceuticals Inc fund operations to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Madrigal Pharmaceuticals Inc (2001–2025)
Total liabilities of Madrigal Pharmaceuticals Inc from 2001 to 2025. This chart illustrates how Madrigal Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Check how resilient are Madrigal Pharmaceuticals Inc's assets to evaluate the company's liquid asset resilience ratio.
Madrigal Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Madrigal Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
China Tungsten and Hightech Materials Co Ltd
SHE:000657
|
China | CN¥18.73 Billion |
|
GAIL (India) Limited
NSE:GAIL
|
India | Rs480.58 Billion |
|
QXO, Inc.
NYSE:QXO
|
USA | $6.50 Billion |
|
Penske Automotive Group Inc
NYSE:PAG
|
USA | $12.64 Billion |
|
Azrieli Group Ltd
TA:AZRG
|
Israel | ILA38.26 Billion |
|
Baxter International Inc
NYSE:BAX
|
USA | $13.61 Billion |
|
Semtech Corporation
NASDAQ:SMTC
|
USA | $898.17 Million |
Liability Composition Analysis (2001–2025)
This chart breaks down Madrigal Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Madrigal Pharmaceuticals Inc asset portfolio.
Liquidity & Leverage Metrics
Madrigal Pharmaceuticals Inc Total Liabilities Ratios Explained
Madrigal Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.52 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Madrigal Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Madrigal Pharmaceuticals Inc (2001–2025)
The table below shows the annual total liabilities of Madrigal Pharmaceuticals Inc from 2001 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $656.90 Million | +128.20% |
| 2024-12-31 | $287.86 Million | +22.38% |
| 2023-12-31 | $235.21 Million | +42.40% |
| 2022-12-31 | $165.18 Million | +113.90% |
| 2021-12-31 | $77.22 Million | +64.22% |
| 2020-12-31 | $47.02 Million | +84.48% |
| 2019-12-31 | $25.49 Million | +201.88% |
| 2018-12-31 | $8.44 Million | -16.01% |
| 2017-12-31 | $10.05 Million | +109.46% |
| 2016-12-31 | $4.80 Million | -73.02% |
| 2015-12-31 | $17.79 Million | -49.95% |
| 2014-12-31 | $35.54 Million | -22.93% |
| 2013-12-31 | $46.11 Million | +64.97% |
| 2012-12-31 | $27.95 Million | +1.46% |
| 2011-12-31 | $27.55 Million | -9.93% |
| 2010-12-31 | $30.59 Million | +27.46% |
| 2009-12-31 | $24.00 Million | -84.62% |
| 2008-12-31 | $156.04 Million | +59.63% |
| 2007-12-31 | $97.75 Million | +72.90% |
| 2006-12-31 | $56.54 Million | +201.80% |
| 2005-12-31 | $18.73 Million | +33.21% |
| 2004-12-31 | $14.06 Million | +302.26% |
| 2003-12-31 | $3.50 Million | +11955.17% |
| 2001-12-31 | $29.00K | -- |
About Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.